Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...
February 08, 2016 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Leerink Partners 5th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
February 03, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs

NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq.,...
January 04, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer

NEW HAVEN, Conn., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that Joel Barrish, Ph.D., has been named the Company’s Chief Scientific Officer...
December 16, 2015 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Appoints Dr. Frank Verwiel to Board of Directors

NEW HAVEN, Conn., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive...
December 05, 2015 17:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development

- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
November 05, 2015 17:51 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter And Nine Month 2015 Financial Results

NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the...
November 05, 2015 09:03 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors

- Highly potent, specific, and oral factor D inhibitors effectively block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells and mitigate the accumulation of C3 fragments – -...
November 02, 2015 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Credit Suisse 24th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
October 16, 2015 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir for the Treatment of Genotype 1 Chronic HCV

NEW HAVEN, Conn., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen)...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right